Form 4: BioXcel CEO Granted 18,000 Restricted Stock Units

BioXcel Therapeutics CEO Vimal Mehta was granted 18,000 Restricted Stock Units, vesting in approximately nine months, as part of his compensation.

Summary

• Vimal Mehta, the CEO, President, and Director of BioXcel Therapeutics, Inc. (BTAI), was granted 18,000 Restricted Stock Units (RSUs).
• The grant date for these RSUs was August 1, 2025.
• Each RSU represents a contingent right to receive one share of BioXcel's Common Stock.
• The RSUs will vest 100% on or within 30 days of 9 months from the grant date (approximately May 1, 2026), contingent on continued employment.
• Following this transaction, Vimal Mehta beneficially owns 18,000 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units to the CEO is a standard compensation practice, generally viewed positively as it aligns executive incentives with long-term shareholder value, but it does not reflect new operational performance or strategic shifts.

Positives

• The grant of Restricted Stock Units aligns management's interests with shareholder value through equity ownership.
• The vesting schedule encourages long-term commitment and retention of a key executive.

Negatives

• There is no immediate cash inflow for the executive from this grant.
• The ultimate value of the RSUs is dependent on future stock price performance.

Risks

• The value of the granted Restricted Stock Units is contingent on the future market price of BioXcel Therapeutics, Inc. common stock.
• Vesting of the RSUs is subject to the reporting person's continued employment with the Issuer or a subsidiary.

Future Outlook

The vesting of the granted Restricted Stock Units is contingent upon Vimal Mehta's continued employment with BioXcel Therapeutics, Inc. or its subsidiaries through the vesting date.

Industry Context

Executive equity grants, such as Restricted Stock Units, are a common practice in the biotechnology and pharmaceutical industries to incentivize leadership and align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a CEO is a standard form of executive compensation across various industries, including biotechnology, designed to align executive incentives with shareholder value creation.

Related Party Transactions

• The grant of Restricted Stock Units to the CEO is a form of executive compensation and a common related-party transaction between a company and its executive officers.

Stakeholder Impact

• Shareholders: Potential long-term alignment of the CEO's interests with shareholder value through equity ownership.
• Employees: This is a standard executive compensation practice and does not directly impact general employees.

Next Steps

• Vesting of the 18,000 Restricted Stock Units on or within 30 days of 9 months from the August 1, 2025 grant date, subject to continued employment.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Vimal Mehta, Restricted Stock Units, RSU grant, executive compensation, insider transaction, Form 4